List view / Grid view
24 March 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives...
24 March 2014 | By The European Medicines Agency
Vynfinit (vintafolide) offers treatment for women with limited therapeutic options; two diagnostic medicines recommended for approval will help identify patients most likely to respond...
24 March 2014 | By The European Medicines Agency
This page provides an overview of the opinions adopted at the March 2014 meeting of the Committee for Medicinal Products for Human Use and other important outcomes...
21 March 2014 | By Novartis
Novartis announced that the Joint Committee on Vaccination and Immunisation in the UK has recommended the inclusion of Bexsero® (Meningococcal Group B Vaccine...
21 March 2014 | By Boehringer Ingelheim
Positive opinion for investigational SGLT2 inhibitor empagliflozin for the treatment of T2D in adults...
21 March 2014 | By Biogen Idec
The approval of ALPROLIX is first significant advance in hemophilia B treatment in more than 17 years ...
21 March 2014 | By The European Medicines Agency
Entyvio (vedolizumab) offers a treatment option for patients who do not respond to standard therapies...
21 March 2014 | By METTLER TOLEDO
Take the worry out of weighing with new balances designed to aid compliance and process security...
20 March 2014 | By AbbVie
AbbVie announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA® (adalimumab)...
20 March 2014 | By Johnson & Johnson
Independent data monitoring committee recommends halting trial and unblinding data based on treatment efficacy...
20 March 2014 | By Novartis
Novartis has announced the launch of the Lucentis® (ranibizumab) pre-filled syringe in Germany, with other markets to follow throughout 2014...
20 March 2014 | By GlaxoSmithKline
GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population...
20 March 2014 | By AstraZeneca
AstraZeneca announced that Ann Cairns will be proposed to shareholders for election as a Non-Executive Director at the Company’s Annual General Meeting on 24 April 2014...
20 March 2014 | By Pfizer Inc.
Pfizer intends to submit biologics license application for bivalent rLP2086 to U.S. Food and Drug Administration by mid-2014...
19 March 2014 | By Janssen
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir...
